Transgene

Equities

TNG

FR0005175080

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 09:24:18 16/07/2024 BST			5-day change	1st Jan Change
1.104 ^EUR	-0.36%		+2.99%	-19.42%

06-03	Transgene: first patient in phase II study	CF
04-10	Transgene: presents vaccine results at AACR	CF

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

January 14, 2021 at 05:00 pm

Transgene announced the appointment of Gaëlle Stadtler as Director of Human Resources. Gaëlle is joining the Executive Committee and will directly report to Hedi Ben Brahim, Chairman and CEO of the company.

Latest news about Transgene

Transgene: first patient in phase II study	06-03	CF
Transgene: presents vaccine results at AACR	04-10	CF
Transgene CFO Steps Down; Successor Assumes Office	03-28	MT
Transcript : Transgene SA, 2023 Earnings Call, Mar 27, 2024	03-27
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Transgene SA Announces Chief Financial Officer Changes	03-27	CI
Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee	03-27	CI
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	03-12	MT
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	03-05	CI
Transgene Appoints Chief Business Officer	01-23	MT
Transgene Appoints James Wentworth as Chief Business Officer and Member of Executive Management Team	01-22	CI
Transgene: new CFO, share price rises	12-06	CF
Biotech Group Transgene Names CFO	12-06	MT
UniQure Says US FDA Clears Investigational New Drug Application for Fabry Disease Candidate	11-29	MT
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	10/10/23	CI
Transcript : Transgene SA, H1 2023 Earnings Call, Sep 20, 2023	20/09/23
Transgene SA Reports Earnings Results for the Half Year Ended June 30, 2023	20/09/23	CI
Transgene Obtains $15 Million from Sale of Minority Stake in Chinese Biopharmaceutical Group	18/07/23	MT
Transgene: proceeds from sale received	18/07/23	CF
4D Molecular Reports Positive Interim Data in Phase 1/2 AEROW Clinical Trial of 4D-710; Shares Jump	07/06/23	MT
TRANSGENE : Invest Securities confirms its Buy rating	06/06/23	CF
Transgene: presents new data at ASCO 2023	06/06/23	CF
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023	06/06/23	CI
BioInvent Ready for Combination Studies with BT-001	05/06/23	CI
TRANSGENE : Invest Securities reiterates its recommendation	05/06/23	CF

Chart Transgene

Duration

Period

More charts

Company Profile

Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.

Sector

Biotechnology & Medical Research

Calendar

24/09/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Transgene

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.108 EUR

Average target price

2.6 EUR

Spread / Average Target

+134.66%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRANSGENE	-19.42%	122M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+25.27%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.75%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs